Puer Tea Extract

About Tasly Pharmaceutical

Tasly Pharmaceuticals Inc. is a pioneering private company, founded in 2006 and headquartered in Rockville, Maryland, that focuses on botanical drug development. Its lead asset, T89 (Dantonic®), is a breakthrough compound for chronic stable angina that has completed a global FDA Phase III trial, positioning it as a potential first-in-class botanical prescription drug. The company leverages a model of rigorous clinical validation and quality control to advance plant-based therapeutics, primarily targeting cardiovascular disease, and aims to establish a new category of synergistic, long-term treatment options alongside conventional medicine.

Therapeutic Areas

Other Hyperlipidemia Drugs